The World Health Organization said they are discontinuing the solidarity trials of Hydroxychloroquine and Lopinavir/Ritonavir as it is not showing any reduction in the death rate hospitalized COVID-19 patients. Here is everything you need to know.
On Saturday, WHO has announced the discontinuation of the solidarity trials of Hydroxychloroquine and Lopinavir/Ritonavir. The Solidarity Trial was created by WHO to identify the effective COVID-19 treatment for critical patients as it has shown very little or no reduction in the death rate of the hospitalized patients, said in a press release.
The Committee formulated the recommendation by creating evidence of Hydroxychloroquine vs standard-of-care and for Lopinavir/Ritonavir vs standard-for-care from the interim trials. And according to this interim trial, there is very little or no reduction has been seen in the mortality rate of hospitalized patients by using Hydroxychloroquine and Lopinavir/Ritonavir drug as the treatment.
WHO has established its solidarity trails in March; it was established to find an effective treatment for hospitalized COVID-19 patients. It was initially started to have five different trials to find the most effective treatment. The trails included standard or usual care, by combining remdesivir and Lopinavir/Ritonavir, interferon combined with Lopinavir/Ritonavir, and at last Hydroxychloroquine and chloroquine combined with all of them.
WHO is targeting to have the fastest treatment to improve survival and disease progression.
Stay Safe. Stay Healthy. Stay Tuned.